Avisa Pharma Inc
Infections in hospitals are the fourth largest killer in the United States. The Avisa BreathTest technology addresses this huge problem.
Avisa Pharma™ Inc. is a clinical stage company developing a proprietary, point-of-care biomarker BreathTest for the rapid and accurate detection and monitoring of patients with Ventilator Associated Pneumonia (VAP) and Cystic Fibrosis (CF) and Tuberculosis (TB). Such multi-drug resistant pathogens compromise lung functionality, morbidity and/mortality. Regulated as a drug/device under a 510k, AV-1 BreathTest is a new use of a marketed product.